Results 211 to 220 of about 25,411 (262)

Comparative analysis of mineralocorticoid receptor antagonists and renin-angiotensin system inhibitors/angiotensin receptor neprilysin inhibitor in heart failure with mildly reduced ejection fraction. [PDF]

Front Pharmacol
Lee CC, Te-Wei Kuan D, Chang KC, Chen ZW, Cheng JF, Lin TT, Lin LY, Wu CK.   +7 more
europepmc   +1 more source

Mineralocorticoid receptor antagonists in adults with resistant hypertension and obstructive sleep apnoea. [PDF]

Aust Prescr
europepmc   +1 more source

Efficacy and safety of mineralocorticoid receptor antagonists for the treatment of low-renin hypertension: a systematic review and meta-analysis. [PDF]

J Hum Hypertens
Shah SS, Zhang J, Gwini SM, Young MJ, Fuller PJ, Yang J.   +5 more
europepmc   +1 more source

Single-cell transcriptomics and chromatin accessibility profiling elucidate the kidney-protective mechanism of mineralocorticoid receptor antagonists. [PDF]

J Clin Invest
Abedini A, Sánchez-Navaro A, Wu J, Klötzer KA, Ma Z, Poudel B, Doke T, Balzer MS, Frederick J, Cernecka H, Liu H, Liang X, Vitale S, Kolkhof P, Susztak K.   +14 more
europepmc   +1 more source

Potential Role of Mineralocorticoid Receptor Antagonists in Nondiabetic Chronic Kidney Disease and Glomerular Disease.

Clin J Am Soc Nephrol
Zachariah T, Radhakrishnan J.
europepmc   +1 more source

パーシャルアゴニスト　カッセイ　ヲ　ユウスル　シンキ　MR　キッコウヤク　ノ　ヤクリ　サヨウ　ニカンスル　ケンキュウ　コウカリウム　ケッショウ　リスク　テイゲンカ　ニ　チャクモク　シタ　シンキ　チリョウ　センリャク [PDF]

ナリアイ, テツロウ, 成相, 哲朗   +1 more
core  

Novel Versus Conventional Sequencing of β-Blockers, Sodium/Glucose Cotransportor 2 Inhibitors, Angiotensin Receptor-Neprilysin Inhibitors, and Mineralocorticoid Receptor Antagonists in Stable Patients With Heart Failure With Reduced Ejection Fraction (NovCon Sequencing Study): Protocol for a Randomized Controlled Trial.

JMIR Res Protoc
Karamchand S, Chipamaunga T, Naidoo P, Naidoo K, Rambiritch V, Ho K, Chilton R, McMahon K, Leisegang R, Weich H, Hassan K.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Mineralocorticoid receptor antagonists

2023
Abstract Hypertension, post-myocardial infarction, and heart failure are the cardiovascular clinical syndromes where mineralocorticoid receptor antagonists (MRAs) have shown a beneficial effect. Most guidelines, while recommending MRAs, do not make a clear recommendation as to which MRAs should be used, how doses should be titrated, or ...
Bertram Pitt, João Pedro Ferreira, Faiez Zannad   +2 more
openaire   +1 more source

Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists

Current Hypertension Reports, 2020
Recently, nonsteroidal mineralocorticoid receptor (MR) antagonists (MRAs), which have been proposed to be called MR blockers (MRBs), have become available for clinical use, but their clinical role is unknown. We reviewed the clinical roles of MRAs and MRBs based on previous knowledge and as demonstrated in representative clinical trials.Steroidal MRAs,
Daisuke, Sueta, Eiichiro, Yamamoto, Kenichi, Tsujita   +2 more
openaire   +2 more sources